Core Viewpoint - ALK has upgraded its full-year financial outlook for 2025 based on strong Q3 performance and positive business momentum in Europe [1] Financial Outlook - Revenue is now expected to grow by 13-15% in local currencies, an increase from the previous forecast of 12-14% [7] - Growth is driven by higher volumes, particularly in allergy immunotherapy (AIT) and anaphylaxis products [7] - The EBIT margin is projected to improve to approximately 26%, up from the previous estimate of 25%, due to revenue growth, gross margin improvements, and optimizations [7] Company Information - ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma, headquartered in Hørsholm, Denmark [5] - The company employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen [5]